Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 5/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654840 | 0.93 | PTGER4 (0.52) | PTGER4MEN1USP2POLBBLM | |
| SCHEMBL5822432 | 0.90 | PTGER4 (0.51) | PTGER4MCHR1CA1CA2TACR2 | |
| SCHEMBL5654076 | 0.86 | PTGER4 (0.72) | PTGER4TACR2CPB1CPB2 | |
| SCHEMBL5654741 | 0.85 | PTGER4 (0.56) | PTGER4CA1CA2CPB1CPB2 | |
| SCHEMBL5655171 | 0.85 | PTGER4 (0.75) | PTGER4MCHR1CA1CA2CPB1 | |
| SCHEMBL5655204 | 0.84 | PTGER4 (0.62) | PTGER4MEN1KMT2ACA1CA2 | |
| SCHEMBL5801537 | 0.81 | PTGER4 (0.50) | PTGER4MCHR1CA1CA2CPB1 | |
| SCHEMBL5652220 | 0.80 | PTGER4 (0.55) | PTGER4 | |
| SCHEMBL5654934 | 0.79 | PTGER4 (0.48) | PTGER4CA1CA2 | |
| SCHEMBL5655164 | 0.78 | PTGER4 (0.48) | PTGER4MCHR1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | PTGER4 1/4885MEN1 4001/4885USP2 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.